

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of )  
QUENTIN-MILLET et al. )  
Serial No. : 08/591,447 )  
Filed: April 18, 1996 )  
)  
For: TBP2 FRAGMENTS OF THE TRANSFERRIN RECEPTOR OF NEISSERIA  
MENINGITIDIS

Examiner: M. Pak

Art Unit: 1812

STATEMENT UNDER 37 C.F.R. § 1.821

Honorable Assistant Commissioner of Patents and Trademarks  
Washington, D.C. 20231

SIR:

I hereby certify in accordance with 37 C.F.R. 1.821(f) that the content of the enclosed paper sequence listing and computer readable form of the sequence listing are the same. In accordance with 37 C.F.R. 1.821(g), I hereby certify that the enclosed submission contains no new matter.

Respectfully submitted,



B. Aaron Schulman  
Registration No. 31,877

February 7, 1997

LARSON AND TAYLOR  
727 - 23rd Street, South  
Arlington, Virginia 22202  
(703) 920-7200



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
08/591,447	04/16/96	QUENTIN NUCLEOTIDE	AT&T/PTO/DOCKET#

THOMAS P SARRO  
LARSON & TAYLOR  
727 23RD STREET SOUTH  
ARLINGTON VA 22202

18N2/1107

EXAMINER

PAK, M

ART UNIT

PAPER NUMBER

1812

DATE MAILED:

11/07/96

12/07/96 (H)

b7B

RECEIVED

NOV 08 1996

LARSON AND TAYLOR

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents

Serial No. 08/591,447  
Art Unit 1812

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and / or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And / Or Amino Acid Sequence Disclosures.

APPLICANT IS GIVEN 30 DAYS FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Michael D. Pak, whose telephone number is (703) 305-7038. The Examiner can normally be reached Mondays through Fridays from 8:30 a.m. to 5:00 p.m. The fax number for the Group is (703) 305-0294.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Stephen Walsh, can be reached at (703) 308-2957.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group Receptionist, whose telephone number is (703) 308-0196.

MOP

Michael Pak  
1812

DAVID L. FITZGERALD  
PRIMARY EXAMINER  
GROUP 1800

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG-29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- 7.

Other: \_\_\_\_\_

**Applicant must provide:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.